Treatment escalation and de-escalation of de-novo metastatic castration-sensitive prostate cancer
S Akamatsu, Y Naito, J Nagayama… - Nagoya Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Androgen receptor signaling inhibitors combined with androgen deprivation therapy have
become the standard of care for metastatic castration-sensitive prostate cancer (mCSPC) …
become the standard of care for metastatic castration-sensitive prostate cancer (mCSPC) …
Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?
MA Gómez-Aparicio, F López-Campos, D Buchser… - Cancers, 2024 - mdpi.com
Simple Summary First-line treatment options for patients with hormone-sensitive metastatic
prostate cancer (mHSPC) have evolved in recent years with treatment intensification …
prostate cancer (mHSPC) have evolved in recent years with treatment intensification …
Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)
BL Maughan, Y Liu, S Mundle, X Wang… - Prostate Cancer and …, 2024 - nature.com
Background Androgen receptor pathway inhibitors (apalutamide [APA], enzalutamide [ENZ],
abiraterone acetate plus prednisone [AAP]) combined with androgen-deprivation therapy …
abiraterone acetate plus prednisone [AAP]) combined with androgen-deprivation therapy …
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
Y Yamamoto, S Fujimoto, M Hashimoto… - International Journal of …, 2024 - Springer
Background Upfront androgen receptor signaling inhibitor (ARSI) along with androgen
deprivation therapy is the current standard of care for metastatic castration-sensitive prostate …
deprivation therapy is the current standard of care for metastatic castration-sensitive prostate …
Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer …
CHM Wong, ICH Ko, DKW Leung, B Siu… - The …, 2025 - Wiley Online Library
Introduction In de novo metastatic hormone‐sensitive prostate cancer (mHSPC) treated with
upfront intensification using androgen receptor signaling inhibitor or chemotherapy …
upfront intensification using androgen receptor signaling inhibitor or chemotherapy …
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
Background To evaluate the impact of prostate‐specific antigen (PSA) nadir, PSA response
and time to PSA nadir (TTN) in metastatic hormone‐sensitive prostate cancer (mHSPC) …
and time to PSA nadir (TTN) in metastatic hormone‐sensitive prostate cancer (mHSPC) …
Erste klinische und onkologische Erfahrungen mit der Triplet-Therapie beim „high-volume “metastasierten hormonsensiblen Prostatakarzinom
M Wenzel, B Hoeh, J Kasparek, C Humke… - Die Urologie, 2024 - Springer
Zusammenfassung Hintergrund Die Behandlung mittels Androgendeprivationstherapie
(ADT) plus erweiterter Hormontherapie (ARTA) stellt die Standardtherapie beim …
(ADT) plus erweiterter Hormontherapie (ARTA) stellt die Standardtherapie beim …
[PDF][PDF] Real-World Comparison of Deep Prostate-Specific Antigen Response in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With …
BH Lowentritt, I Khilfeh, D Pilon - Rev Urol, 2024 - articles-cdn.specialtynetworks.com
FINAL_ISSUE 2 Page 1 REVIEWS IN UROLOGY 29 Reviews In Urology | 2024, Vol 23,
Issue 2 Prostate Cancer (Review) Citation: Lowentritt BH, Khilfeh I, Pilon D, et al. Real-world …
Issue 2 Prostate Cancer (Review) Citation: Lowentritt BH, Khilfeh I, Pilon D, et al. Real-world …
First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer
M Wenzel, B Hoeh, J Kasparek, C Humke… - Urologie (Heidelberg …, 2023 - europepmc.org
Zusammenfassung Hintergrund: Die Behandlung mittels Androgendeprivationstherapie
(ADT) plus erweiterter Hormontherapie (ARTA) stellt die Standardtherapie beim …
(ADT) plus erweiterter Hormontherapie (ARTA) stellt die Standardtherapie beim …
Triage of High-Risk Cancer Patients Through Imaging, Genetic, and Integrative Approaches
JL Couetil - 2024 - scholarworks.iupui.edu
Metastasis, the spread of cancer cells from their original site to other body parts, is
responsible for 90% of cancer mortality. This work applies machine learning and …
responsible for 90% of cancer mortality. This work applies machine learning and …